NasdaqGM:TELA

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction.


Snowflake Analysis

Adequate balance sheet with limited growth.

Share Price & News

How has TELA Bio's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: TELA's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-0.7%

TELA

4.4%

US Medical Equipment

1.6%

US Market


1 Year Return

n/a

TELA

6.1%

US Medical Equipment

4.8%

US Market

Return vs Industry: Insufficient data to determine how TELA performed against the US Medical Equipment industry.

Return vs Market: Insufficient data to determine how TELA performed against the US Market.


Shareholder returns

TELAIndustryMarket
7 Day-0.7%4.4%1.6%
30 Day-19.7%-0.04%2.3%
90 Day70.6%22.3%29.5%
1 Yearn/a7.0%6.1%7.1%4.8%
3 Yearn/a57.6%53.2%37.1%28.1%
5 Yearn/a107.6%91.4%67.2%48.6%

Price Volatility Vs. Market

How volatile is TELA Bio's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is TELA Bio undervalued compared to its fair value and its price relative to the market?

6.43x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: Insufficient data to calculate TELA's fair value to establish if it is undervalued.

Significantly Below Fair Value: Insufficient data to calculate TELA's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: TELA is unprofitable, so we can't compare its PE Ratio to the Medical Equipment industry average.

PE vs Market: TELA is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate TELA's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: TELA is overvalued based on its PB Ratio (6.4x) compared to the US Medical Equipment industry average (3.7x).


Next Steps

Future Growth

How is TELA Bio forecast to perform in the next 1 to 3 years based on estimates from 4 analysts?

0.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: TELA is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: TELA is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: TELA is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: TELA's revenue (42.8% per year) is forecast to grow faster than the US market (9.3% per year).

High Growth Revenue: TELA's revenue (42.8% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if TELA's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has TELA Bio performed over the past 5 years?

-3.4%

Last years earnings growth


Earnings and Revenue History

Quality Earnings: TELA is currently unprofitable.

Growing Profit Margin: TELA is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: Insufficient data to determine if TELA's year-on-year earnings growth rate was positive over the past 5 years.

Accelerating Growth: Unable to compare TELA's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: TELA is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (3.4%).


Return on Equity

High ROE: TELA has a negative Return on Equity (-97.74%), as it is currently unprofitable.


Next Steps

Financial Health

How is TELA Bio's financial position?


Financial Position Analysis

Short Term Liabilities: TELA's short term assets ($55.3M) exceed its short term liabilities ($4.2M).

Long Term Liabilities: TELA's short term assets ($55.3M) exceed its long term liabilities ($30.4M).


Debt to Equity History and Analysis

Debt Level: TELA's debt to equity ratio (124.1%) is considered high.

Reducing Debt: Insufficient data to determine if TELA's debt to equity ratio has reduced over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: TELA has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: TELA has sufficient cash runway for 1.7 years if free cash flow continues to reduce at historical rates of 22.5% each year.


Next Steps

Dividend

What is TELA Bio current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate TELA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate TELA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if TELA's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if TELA's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of TELA's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

1.5yrs

Average management tenure


CEO

Antony Koblish (54yo)

8.25yrs

Tenure

US$2,399,605

Compensation

Mr. Antony Koblish is an Operating Partner of 1315 Capital LLC. Mr. Koblish serves as the President, Director and Chief Executive Officer of TELA Bio, Inc. since April 2012, which he co-founded in April 20 ...


CEO Compensation Analysis

Compensation vs Market: Antony's total compensation ($USD2.40M) is above average for companies of similar size in the US market ($USD1.35M).

Compensation vs Earnings: Antony's compensation has increased whilst the company is unprofitable.


Leadership Team

NamePositionTenureCompensationOwnership
Antony Koblish
Co-founder8.25yrsUS$2.40m1.07% $2.1m
Maarten Persenaire
Co-Founder & Chief Medical Officer7.58yrsUS$907.67k0.55% $1.1m
E. Greenhalgh
Chief Technology Officer3.58yrsUS$844.92k0.073% $143.5k
Nora Brennan
Chief Financial Officer1.5yrsno data0.025% $50.1k
Michael Leonard
Vice President of Operationsno datano datano data
Stuart Henderson
Vice President of Corporate Development & Investor Relations1.5yrsno datano data
Christopher Smith
Vice President of Salesno datano datano data
Paul Talmo
Chief of Strategy0.50yrno datano data
Peter Murphy
Chief Commercial Officer0.50yrno datano data
Francis Conway
VP of Financeno datano datano data

1.5yrs

Average Tenure

53yo

Average Age

Experienced Management: TELA's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.


Board Members

NamePositionTenureCompensationOwnership
Antony Koblish
Co-founder8.25yrsUS$2.40m1.07% $2.1m
Adele Oliva
Independent Director8.5yrsUS$43.40kno data
Federica O'Brien
Independent Director0.67yrUS$63.17kno data
Douglas Evans
Independent Chairman0.25yrno datano data
Lisa Colleran
Independent Director0.25yrno datano data
Kurt Azarbarzin
Independent Director1.67yrsUS$78.72kno data
Vince Burgess
Independent Director7.58yrsUS$66.79kno data

1.7yrs

Average Tenure

56yo

Average Age

Experienced Board: TELA's board of directors are not considered experienced ( 1.7 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: TELA only recently listed within the past 12 months.


Top Shareholders

Company Information

TELA Bio, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: TELA Bio, Inc.
  • Ticker: TELA
  • Exchange: NasdaqGM
  • Founded: 2012
  • Industry: Health Care Supplies
  • Sector: Healthcare
  • Market Cap: US$196.664m
  • Shares outstanding: 14.41m
  • Website: https://www.telabio.com

Number of Employees


Location

  • TELA Bio, Inc.
  • 1 Great Valley Parkway
  • Suite 24
  • Malvern
  • Pennsylvania
  • 19355
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
TELANasdaqGM (Nasdaq Global Market)YesCommon StockUSUSDNov 2019

Biography

TELA Bio, Inc., a medical technology company, focuses on the design, development, and marketing of tissue reinforcement materials to address unmet needs in soft tissue reconstruction. The company provides a portfolio of OviTex Reinforced Tissue Matrix (OviTex) products for hernia repair and abdominal wall reconstruction; and OviTex PRS Reinforced Tissue Matrix products to address the unmet needs in plastic and reconstructive surgery, as well as OviTex for Laparoscopic and Robotic Procedures, a sterile reinforced tissue matrix derived from ovine rumen with polypropylene fiber intended to be used in laparoscopic and robotic-assisted hernia surgical repairs. It markets its products through a single direct sales force, principally in the United States. The company was founded in 2012 and is headquartered in Malvern, Pennsylvania. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/07/03 00:22
End of Day Share Price2020/07/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.